Drug application
MICAFUNGIN SODIUM (MICAFUNGIN SODIUM)
Drugs@FDA ANDA 211713 · XELLIA PHARMS APS
Key facts
| Drug name | MICAFUNGIN SODIUM |
|---|---|
| Active ingredients | MICAFUNGIN SODIUM |
| Application type | ANDA |
| Application number | 211713 |
| Company | XELLIA PHARMS APS |
| Dosage forms | INJECTABLE, INTRAVENOUS |
| Strength | EQ 50MG BASE/VIAL |
| Marketing status | Prescription |
| TE codes | AP |
| Reference listed drug | No |
| Latest submission status date | Jun 2, 2021 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- 10–99 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.